Top

Published in:

01-11-2013 | Original Article

Expression of the chemokine decoy receptor D6 is decreased in colon adenocarcinomas

Authors: Veronica Langenes, Helena Svensson, Lars Börjesson, Bengt Gustavsson, Mats Bemark, Åsa Sjöling, Marianne Quiding-Järbrink

Published in: Cancer Immunology, Immunotherapy | Issue 11/2013

Abstract

Recruitment of immune cells to tumors is a complex process crucial for both inflammation-driven tumor progression and specific anti-tumor cytotoxicity. Chemokines control the directed migration of immune cells, and their actions are partly controlled by nonsignaling chemokine decoy receptors. The role of the receptors such as D6, Duffy antigen receptor for chemokines and ChemoCentryx chemokine receptor in immunity to tumors is still unclear. Using real-time PCR, we detected significantly decreased expression of D6 mRNA in colon tumors compared to unaffected mucosa. D6 protein was expressed by lymphatic endothelium and mononuclear cells in the colon lamina propria and detected by immunohistochemistry in two out of six tissue samples containing high D6 mRNA levels, whereas no staining was observed in any tissue samples expressing low mRNA levels. When examining the density of lymphatic vessels in colon tumors, we detected a marked increase in vessels identified by the lymphatic endothelial marker Lyve-1, excluding passive regulation of D6 due to decreased lymphatic vessel density. In parallel, the Treg-recruiting chemokine CCL22, which is sequestered by D6, was threefold increased in tumor tissue. Furthermore, we could show that low D6 expression correlated to more invasive tumors and that tumor location influences D6 expression, which is lower in the more distal parts of the colon. The data support that regulation of D6 by colon tumors results in altered levels of proinflammatory CC chemokines, thereby shaping the local chemokine network to favor tumor survival. This may have implications for the design of future immunotherapy for colon cancer.

Zou W (2005) Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer 5(4):263–274. doi:10.1038/nrc1586 PubMedCrossRef

Rossi D, Zlotnik A (2000) The biology of chemokines and their receptors. Annu Rev Immunol 18:217–242PubMedCrossRef

Zlotnik A, Yoshie O (2000) Chemokines: a new classification system and their role in immunity. Immunity 12(2):121–127PubMedCrossRef

Kiefer F, Siekmann AF (2011) The role of chemokines and their receptors in angiogenesis. Cell Mol Life Sci 68(17):2811–2830. doi:10.1007/s00018-011-0677-7 PubMedCrossRef

Verbeke H, Struyf S, Laureys G, Van Damme J (2011) The expression and role of CXC chemokines in colorectal cancer. Cytokine & growth factor rev 22(5–6):345–358. doi:10.1016/j.cytogfr.2011.09.002 CrossRef

Wang D, Dubois RN, Richmond A (2009) The role of chemokines in intestinal inflammation and cancer. Current opinion in pharmacology 9(6):688–696. doi:10.1016/j.coph.2009.08.003 PubMedCrossRef

Murphy PM, Baggiolini M, Charo IF, Hebert CA, Horuk R, Matsushima K, Miller LH, Oppenheim JJ, Power CA (2000) International union of pharmacology. XXII. Nomenclature for chemokine receptors. Pharmacol Rev 52(1):145–176PubMed

Allen SJ, Crown SE, Handel TM (2007) Chemokine: receptor structure, interactions, and antagonism. Annu Rev Immunol 25:787–820. doi:10.1146/annurev.immunol.24.021605.090529 PubMedCrossRef

Bonini JA, Martin SK, Dralyuk F, Roe MW, Philipson LH, Steiner DF (1997) Cloning, expression, and chromosomal mapping of a novel human CC-chemokine receptor (CCR10) that displays high-affinity binding for MCP-1 and MCP-3. DNA Cell Biol 16(10):1249–1256PubMedCrossRef

10.

Gosling J, Dairaghi DJ, Wang Y, Hanley M, Talbot D, Miao Z, Schall TJ (2000) Cutting edge: identification of a novel chemokine receptor that binds dendritic cell- and T cell-active chemokines including ELC, SLC, and TECK. J Immunol 164(6):2851–2856PubMed

11.

Horuk R, Chitnis CE, Darbonne WC, Colby TJ, Rybicki A, Hadley TJ, Miller LH (1993) A receptor for the malarial parasite Plasmodium vivax: the erythrocyte chemokine receptor. Science 261(5125):1182–1184PubMedCrossRef

12.

Nibbs RJ, Wylie SM, Yang J, Landau NR, Graham GJ (1997) Cloning and characterization of a novel promiscuous human beta-chemokine receptor D6. J Biol Chem 272(51):32078–32083PubMedCrossRef

13.

Bonecchi R, Locati M, Galliera E, Vulcano M, Sironi M, Fra AM, Gobbi M, Vecchi A, Sozzani S, Haribabu B, Van Damme J, Mantovani A (2004) Differential recognition and scavenging of native and truncated macrophage-derived chemokine (macrophage-derived chemokine/CC chemokine ligand 22) by the D6 decoy receptor. J Immunol 172(8):4972–4976PubMed

14.

Fra AM, Locati M, Otero K, Sironi M, Signorelli P, Massardi ML, Gobbi M, Vecchi A, Sozzani S, Mantovani A (2003) Cutting edge: scavenging of inflammatory CC chemokines by the promiscuous putatively silent chemokine receptor D6. J Immunol 170(5):2279–2282PubMed

15.

Galliera E, Jala VR, Trent JO, Bonecchi R, Signorelli P, Lefkowitz RJ, Mantovani A, Locati M, Haribabu B (2004) Beta-arrestin-dependent constitutive internalization of the human chemokine decoy receptor D6. J Biol Chem 279(24):25590–25597. doi:10.1074/jbc.M400363200 PubMedCrossRef

16.

Singh MD, King V, Baldwin H, Burden D, Thorrat A, Holmes S, McInnes IB, Nicoll R, Shams K, Pallas K, Jamieson T, Lee KM, Carballido JM, Rot A, Graham GJ (2012) Elevated expression of the chemokine-scavenging receptor d6 is associated with impaired lesion development in psoriasis. Am J Pathol 181(4):1158–1164. doi:10.1016/j.ajpath.2012.06.042 PubMedCrossRef

17.

Lee KM, McKimmie CS, Gilchrist DS, Pallas KJ, Nibbs RJ, Garside P, McDonald V, Jenkins C, Ransohoff R, Liu L, Milling S, Cerovic V, Graham GJ (2011) D6 facilitates cellular migration, and fluid flow, to lymph nodes by suppressing lymphatic congestion. Blood. doi:10.1182/blood-2011-03-344044

18.

Hansell CA, Schiering C, Kinstrie R, Ford L, Bordon Y, McInnes IB, Goodyear CS, Nibbs RJ (2011) Universal expression and dual function of the atypical chemokine receptor D6 on innate-like B cells in mice. Blood 117(20):5413–5424. doi:10.1182/blood-2010-11-317115 PubMedCrossRef

19.

McKimmie CS, Fraser AR, Hansell C, Gutierrez L, Philipsen S, Connell L, Rot A, Kurowska-Stolarska M, Carreno P, Pruenster M, Chu CC, Lombardi G, Halsey C, McInnes IB, Liew FY, Nibbs RJ, Graham GJ (2008) Hemopoietic cell expression of the chemokine decoy receptor D6 is dynamic and regulated by GATA1. J Immunol 181(11):8171–8181PubMed

20.

Nibbs RJ, Kriehuber E, Ponath PD, Parent D, Qin S, Campbell JD, Henderson A, Kerjaschki D, Maurer D, Graham GJ, Rot A (2001) The beta-chemokine receptor D6 is expressed by lymphatic endothelium and a subset of vascular tumors. Am J Pathol 158(3):867–877PubMedCrossRef

21.

Dawson TC, Lentsch AB, Wang Z, Cowhig JE, Rot A, Maeda N, Peiper SC (2000) Exaggerated response to endotoxin in mice lacking the Duffy antigen/receptor for chemokines (DARC). Blood 96(5):1681–1684PubMed

22.

Rot A (2005) Contribution of Duffy antigen to chemokine function. Cytokine Growth Factor Rev 16(6):687–694. doi:10.1016/j.cytogfr.2005.05.011 PubMedCrossRef

23.

Graham GJ (2009) D6 and the atypical chemokine receptor family: novel regulators of immune and inflammatory processes. Eur J Immunol 39(2):342–351. doi:10.1002/eji.200838858 PubMedCrossRef

24.

Middleton J, Neil S, Wintle J, Clark-Lewis I, Moore H, Lam C, Auer M, Hub E, Rot A (1997) Transcytosis and surface presentation of IL-8 by venular endothelial cells. Cell 91(3):385–395PubMedCrossRef

25.

Pruenster M, Mudde L, Bombosi P, Dimitrova S, Zsak M, Middleton J, Richmond A, Graham GJ, Segerer S, Nibbs RJ, Rot A (2009) The Duffy antigen receptor for chemokines transports chemokines and supports their promigratory activity. Nat Immunol 10(1):101–108. doi:10.1038/ni.1675 PubMedCrossRef

26.

Townson JR, Nibbs RJ (2002) Characterization of mouse CCX-CKR, a receptor for the lymphocyte-attracting chemokines TECK/mCCL25, SLC/mCCL21 and MIP-3beta/mCCL19: comparison to human CCX-CKR. Eur J Immunol 32(5):1230–1241. doi:10.1002/1521-4141(200205)32:5<1230:AID-IMMU1230>3.0.CO;2-L PubMedCrossRef

27.

Comerford I, Nibbs RJ, Litchfield W, Bunting M, Harata-Lee Y, Haylock-Jacobs S, Forrow S, Korner H, McColl SR (2010) The atypical chemokine receptor CCX-CKR scavenges homeostatic chemokines in circulation and tissues and suppresses Th17 responses. Blood 116(20):4130–4140. doi:10.1182/blood-2010-01-264390 PubMedCrossRef

28.

Heinzel K, Benz C, Bleul CC (2007) A silent chemokine receptor regulates steady-state leukocyte homing in vivo. Proc Natl Acad Sci USA 104(20):8421–8426. doi:10.1073/pnas.0608274104 PubMedCrossRef

29.

Addison CL, Belperio JA, Burdick MD, Strieter RM (2004) Overexpression of the duffy antigen receptor for chemokines (DARC) by NSCLC tumor cells results in increased tumor necrosis. BMC Cancer 4:28. doi:10.1186/1471-2407-4-28 PubMedCrossRef

30.

Shen H, Schuster R, Stringer KF, Waltz SE, Lentsch AB (2006) The Duffy antigen/receptor for chemokines (DARC) regulates prostate tumor growth. FASEB J 20(1):59–64. doi:10.1096/fj.05-4764com PubMedCrossRef

31.

Feng LY, Ou ZL, Wu FY, Shen ZZ, Shao ZM (2009) Involvement of a novel chemokine decoy receptor CCX-CKR in breast cancer growth, metastasis and patient survival. Clin Cancer Res 15(9):2962–2970. doi:10.1158/1078-0432.CCR-08-2495 PubMedCrossRef

32.

Wu FY, Ou ZL, Feng LY, Luo JM, Wang LP, Shen ZZ, Shao ZM (2008) Chemokine decoy receptor d6 plays a negative role in human breast cancer. Mol Cancer Res 6(8):1276–1288. doi:10.1158/1541-7786.MCR-07-2108 PubMedCrossRef

33.

Zeng XH, Ou ZL, Yu KD, Feng LY, Yin WJ, Li J, Shen ZZ, Shao ZM (2010) Coexpression of atypical chemokine binders (ACBs) in breast cancer predicts better outcomes. Breast Cancer Res Treat. doi:10.1007/s10549-010-0875-2

34.

Zhu Z, Sun Z, Wang Z, Guo P, Zheng X, Xu H (2013) Prognostic impact of atypical chemokine receptor expression in patients with gastric cancer. J Surg Res 183(1):177–183. doi:10.1016/j.jss.2013.01.023 PubMedCrossRef

35.

Bordon Y, Hansell CA, Sester DP, Clarke M, Mowat AM, Nibbs RJ (2009) The atypical chemokine receptor D6 contributes to the development of experimental colitis. J Immunol 182(8):5032–5040. doi:10.4049/jimmunol.0802802 PubMedCrossRef

36.

Vetrano S, Borroni EM, Sarukhan A, Savino B, Bonecchi R, Correale C, Arena V, Fantini M, Roncalli M, Malesci A, Mantovani A, Locati M, Danese S (2010) The lymphatic system controls intestinal inflammation and inflammation-associated Colon Cancer through the chemokine decoy receptor D6. Gut 59(2):197–206. doi:10.1136/gut.2009.183772 PubMedCrossRef

37.

Pfaffl MW (2001) A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 29(9):e45PubMedCrossRef

38.

Neote K, Darbonne W, Ogez J, Horuk R, Schall TJ (1993) Identification of a promiscuous inflammatory peptide receptor on the surface of red blood cells. J Biol Chem 268(17):12247–12249PubMed

39.

Neote K, Mak JY, Kolakowski LF Jr, Schall TJ (1994) Functional and biochemical analysis of the cloned Duffy antigen: identity with the red blood cell chemokine receptor. Blood 84(1):44–52PubMed

40.

Nibbs RJ, Gilchrist DS, King V, Ferra A, Forrow S, Hunter KD, Graham GJ (2007) The atypical chemokine receptor D6 suppresses the development of chemically induced skin tumors. J Clin Invest 117(7):1884–1892. doi:10.1172/JCI30068 PubMedCrossRef

41.

Jamieson T, Cook DN, Nibbs RJ, Rot A, Nixon C, McLean P, Alcami A, Lira SA, Wiekowski M, Graham GJ (2005) The chemokine receptor D6 limits the inflammatory response in vivo. Nat Immunol 6(4):403–411. doi:10.1038/ni1182 PubMedCrossRef

42.

Whitehead GS, Wang T, DeGraff LM, Card JW, Lira SA, Graham GJ, Cook DN (2007) The chemokine receptor D6 has opposing effects on allergic inflammation and airway reactivity. Am J Respir Crit Care Med 175(3):243–249. doi:10.1164/rccm.200606-839OC PubMedCrossRef

43.

Mantovani A, Gray PA, Van Damme J, Sozzani S (2000) Macrophage-derived chemokine (MDC). J Leukoc Biol 68(3):400–404PubMed

44.

Svensson Helena VO, Hanna Stenstad, Stellan Björck, Lars Börjesson, Bengt Gustavsson, Åsa Sjöling, Marianne Quiding-Järbrink (2011) Accumulation of aEb7 expressing and CTLA4hi FoxP3+CD25hi regulatory T cells in colon adenocarcinomas. Manuscript, unpublished

45.

Nishikawa H, Sakaguchi S (2010) Regulatory T cells in tumor immunity. Int J Cancer 127(4):759–767. doi:10.1002/ijc.25429 PubMed

46.

Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, Evdemon-Hogan M, Conejo-Garcia JR, Zhang L, Burow M, Zhu Y, Wei S, Kryczek I, Daniel B, Gordon A, Myers L, Lackner A, Disis ML, Knutson KL, Chen L, Zou W (2004) Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 10(9):942–949. doi:10.1038/nm1093 PubMedCrossRef

47.

Gobert M, Treilleux I, Bendriss-Vermare N, Bachelot T, Goddard-Leon S, Arfi V, Biota C, Doffin AC, Durand I, Olive D, Perez S, Pasqual N, Faure C, Ray-Coquard I, Puisieux A, Caux C, Blay JY, Menetrier-Caux C (2009) Regulatory T cells recruited through CCL22/CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical outcome. Cancer Res 69(5):2000–2009. doi:10.1158/0008-5472.CAN-08-2360 PubMedCrossRef

48.

Mailloux AW, Young MR (2009) NK-dependent increases in CCL22 secretion selectively recruits regulatory T cells to the tumor microenvironment. J Immunol 182(5):2753–2765. doi:10.4049/jimmunol.0801124 PubMedCrossRef

49.

Enarsson K, Lundgren A, Kindlund B, Hermansson M, Roncador G, Banham AH, Lundin BS, Quiding-Jarbrink M (2006) Function and recruitment of mucosal regulatory T cells in human chronic Helicobacter pylori infection and gastric adenocarcinoma. Clin Immunol 121(3):358–368. doi:10.1016/j.clim.2006.07.002 PubMedCrossRef

50.

Berin MC, Dwinell MB, Eckmann L, Kagnoff MF (2001) Production of MDC/CCL22 by human intestinal epithelial cells. Am J Physiol Gastrointest Liver Physiol 280(6):G1217–G1226PubMed

Title: Expression of the chemokine decoy receptor D6 is decreased in colon adenocarcinomas
Authors: Veronica Langenes
Helena Svensson
Lars Börjesson
Bengt Gustavsson
Mats Bemark
Åsa Sjöling
Marianne Quiding-Järbrink
Publication date: 01-11-2013
Publisher: Springer Berlin Heidelberg
Published in: Cancer Immunology, Immunotherapy / Issue 11/2013
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI: https://doi.org/10.1007/s00262-013-1472-0

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 11/2013

Recipient leukocyte infusion enhances the local and systemic graft-versus-neuroblastoma effect of allogeneic bone marrow transplantation in mice

The immunogenicity of a novel cytotoxic T lymphocyte epitope from tumor antigen PL2L60 could be enhanced by 4-chlorophenylalanine substitution at position 1

Myeloid-derived suppressor cells are associated with disease progression and decreased overall survival in advanced-stage melanoma patients

A cytokine cocktail directly modulates the phenotype of DC-enriched anti-tumor T cells to convey potent anti-tumor activities in a murine model

Myeloid-derived suppressor cell function is reduced by Withaferin A, a potent and abundant component of Withania somnifera root extract

Tumor-associated neutrophils (TAN) develop pro-tumorigenic properties during tumor progression

Keynote webinar | Spotlight on antibody–drug conjugates in cancer